Biohemp International Inc. (fka BKIT)

[sweet crude]

Email alert out! (read)

Dear Shareholders,

I just wanted to update you as things are beginning to move forward in our efforts to establish trading back 'current' with OTC Markets.

The Company has retained an additional law firm that specializes in FINRA and trading compliance, and this should be a big help in assisting us in filing a new 15c2-11 to regain normal trading status once again.

We have many announcements and plans we would love to release to out to the market, but until we regain normal trading status we feel best to hold off on these until a proper market can be established. Once this is achieved we expect to have a number of releases regarding plans to build distribution channels and develop a CBD and cannabis venture firm focused on this industry.

For now, trading can still be achieved by placing orders either by phone with your brokerage firm, or online with some platforms by setting limit order good to cancel. If any orders match buy or sell orders currently listed they will most likely result in an execution on level 2.

Of course our main aim is to regain current trading status, and with our new law firm in place we feel we could see results in this matter move ahead quickly in the coming few weeks, if not sooner.

CBD Business Plans

We have a number of venture projects in the works that we plan to announce once proper trading resumes. The recent downturn in CBD sector due to pending FDA regulatory changes offers us an opportunity to structure our business model to one of a service oriented, or venture investment firm within the CBD and cannabis industry, which we feel could remove any direct regulatory issues in regards to marketing and selling CBD infused products.

The Company plans to provide a more detailed overview plan on this in the near future.


New Team Members

During this time we will also be working to build up our team of advisers behind the company, which we intend to update in the coming weeks. You can visit our TEAM section of our website to get updates as new advisers are appointed. https://biohempinternational.com/team/


Recent Interview

You can also access a recent interview we conducted early in Sept. 2019 as we plan to hold more of these type interviews to help keep market informed. You can visit the interview by visiting https://wallstreetnewscast.com/investors/bkit/


Shareholder Communication

One of our biggest focuses, beside our trading compliance, is to establish a more transparent line of communication with our shareholders during these difficult times. No doubt the company has run into a major hurdle it did not foresee in the past couple months, but we feel these are the exact moments when a company should step out and communicate with its shareholders the best it can to keep them informed.

We will continue to work on providing weekly updates through our investor mailing list, social media platforms, and possibly interviews with some outlets to make sure we are keeping everyone updated on current developments, and where things stand as we move forward.

We know it has been trying times for our shareholders, as well as for the company, but rest assured we continue to work behind the scenes to address the issues needed to bring us back into good trading standards, and will work on keeping all of you updated as best we can as we move forward.

Daniel Blum,
CEO & President
BioHemp International (OTC:BKIT)



Twitter: Investors can follow us on our official Twitter account, which we plan to use to keep followers updates on non-material events regarding the company. Users can follow us at https://twitter.com/BiohempB

Mailing List: Investors can also join our investor mailing list to receive updates on news, and special announcements, and add their mailing list for future investor packets and brochures as we begin our marketing and advertisement campaigns. Users can join our mailing list by going to https://www.biohempinternational.com/investors/


Daniel Blum
President

BioHemp International Inc.
244 5th Avenue Suite A-154
New York, NY 10001
Office: [phone]